Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction (CHIARA MIA 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02452515
Recruitment Status : Completed
First Posted : May 22, 2015
Last Update Posted : November 7, 2017
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:
The purpose of the trial is the analysis of safety and tolerability of the chymase inhibitor BAY1142524 in comparison to placebo using a 2 weeks treatment period in clinically stable patients with left-ventricular dysfunction after myocardial infarction. BAY1142524 or placebo will be given on top of evidence-based standard of care for left-ventricular dysfunction after myocardial infarction. Primary objectives are the analysis of safety and tolerability as evidenced by the incidence and severity of adverse events. BAY1142524 will be administered in a parallel group design using four doses (5, 10, 25 mg twice daily, and 50 mg once daily). Each dose group consists of 9 patients treated with verum and 3 patients treated with placebo.

Condition or disease Intervention/treatment Phase
Heart Failure Drug: BAY1142524 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Other
Official Title: A Single-blind, Multicenter Pilot Study to Investigate the Safety and Tolerability of a 14 Day Oral Treatment With Different Doses of the Chymase Inhibitor BAY1142524 in Comparison to Placebo in Clinically Stable Patients With Left-ventricular Dysfunction After Myocardial Infarction
Study Start Date : July 2015
Actual Primary Completion Date : January 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Arm Intervention/treatment
Experimental: BAY1142524 (5 mg)
12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
Drug: BAY1142524
5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks

Drug: Placebo
The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.

Experimental: BAY1142524 (10 mg)
12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
Drug: BAY1142524
10 mg BAY1142524 or placebo given as 2 x 5 mg IR tablets twice daily as for 2 weeks

Drug: Placebo
The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.

Experimental: BAY1142524 (25 mg)
12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
Drug: BAY1142524
25 mg BAY1142524 or placebo given as 5 x 5 mg IR tablets twice daily for 2 weeks

Drug: Placebo
The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.

Experimental: BAY1142524 (50 mg)
12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
Drug: BAY1142524
50 mg BAY1142524 or placebo given 1 x 50 mg IR tablet once daily for 2 weeks

Drug: Placebo
The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.




Primary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: Up to 20 days ]
  2. Number of participants with serious adverse events [ Time Frame: Up to 20 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinically stable patients with left-ventricular dysfunction (LVEF ≤ 45%) after myocardial infarction, whereby the MI occurred 6 or more months before randomization.

    • New York Heart Association (NYHA) class I-II.
    • Left-ventricular ejection fraction ≤ 45%, confirmed by any imaging technique within the last 3 months prior to screening visit will be accepted for screening purposes. If no data are available, an echocardiography has to be performed at screening for inclusion.
    • Treatment with evidence-based therapy for left-ventricular dysfunction post MI for at least 4 weeks prior to screening visit. This therapy has to include at least an Angiotensin-converting enzyme (ACE) inhibitor or an Angiotensin receptor blockers (ARB). Beta-blockers, diuretics, mineralocorticoid receptor antagonist (MRAs), antiplatelet therapy, statins, and aspirin are to be used if indicated. Treatment with stable doses of ACE inhibitors or ARBs using at least half of the recommended target dose (as defined in the European Society of Cardiology (ESC) guidelines, see appendix 16.4) ≥ 4 weeks prior to the screening visit is mandatory.
    • No planned changes to post MI drug therapy during the active treatment phase of the study.
    • Men or confirmed postmenopausal women (defined as being amenorrheic for longer than 2 years with an appropriate clinical profile, e.g. age appropriate and a history of vasomotor symptoms) or women without childbearing potential based on surgical treatment such as bilateral tubal ligation, bilateral oophorectomy or hysterectomy (documented by medical report verification).

Men of reproductive potential must agree to use 2 reliable and acceptable methods for contraception simultaneously when sexually active and not to act as sperm donor. This applies for the time period between signing of the informed consent form and 12 weeks after the last administration of study drug.

Acceptable methods of contraception include, but are not limited to, (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm or cervical cap with spermicide; (iii) intra-uterine device; (iv) hormone-based contraception.

  • Age: 40 to 79 years (inclusive) at the screening visit.
  • Race: Caucasian

Exclusion Criteria:

  • Non-ischemic causes for cardiomyopathy will be excluded (including, but not limited to: primary cardiomyopathy, constrictive, restrictive or hypertrophic cardiomyopathy, acute myocarditis, cardiomyopathy secondary to cardiotoxic chemotherapeutic agents).
  • Hospitalization for decompensated heart failure within the last 3 months prior to randomization.
  • Coronary revascularization within 6 weeks prior to randomization or if revascularization is anticipated or needed during the study duration.
  • Clinically relevant, cardiac ischemia in a stress test within 3 months before screening.
  • Patients carrying implantable cardioverter defibrillators, cardiac resynchronisation therapy devices or left ventricular assist devices that had any significant clinical events requiring treatment or changes to background medical therapy such as ventricular tachycardias, ventricular fibrillation in the last 6 months before randomization while carrying the devices
  • Primary and uncorrected valvular disease with foreseen requirement of valve repair within the next 6 months.
  • Any stroke, TIA, any acute coronary syndrome within 6 months prior to randomization.
  • Clinically relevant hepatic dysfunction at the screening visit indicated by at least one of the following:
  • hepatic insufficiency (Child-Pugh B or C) as documented in medical history
  • total bilirubin > 2 times the upper limit normal (ULN) and
  • alanine amino transferase (ALT) > 3 times the ULN or
  • glutamate dehydrogenase (GLDH) > 3 times the ULN or
  • gamma glutamyl transpeptidase (GGT) > 5 times the ULN.
  • Systolic blood pressure below 100 or above 160 mm Hg at the screening visit based on the average of 3 readings taken from the arm with the highest recordings.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02452515


Locations
Layout table for location information
Denmark
Copenhagen Ø, Denmark, 2100
Copenhagen, Denmark, DK-2400
Hellerup, Denmark, 2900
Herlev, Denmark, 2730
Germany
Frankfurt, Hessen, Germany, 60594
Düsseldorf, Nordrhein-Westfalen, Germany, 40225
Erfurt, Thüringen, Germany, 99084
Berlin, Germany, 13353
Italy
Bergamo, Lombardia, Italy, 24127
Brescia, Lombardia, Italy, 25123
Sponsors and Collaborators
Bayer
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer

Additional Information:
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT02452515     History of Changes
Other Study ID Numbers: 17055
2014-005297-12 ( EudraCT Number )
First Posted: May 22, 2015    Key Record Dates
Last Update Posted: November 7, 2017
Last Verified: March 2017

Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Ventricular Dysfunction
Ventricular Dysfunction, Left
Heart Diseases
Cardiovascular Diseases